Decision XX/4: Campaign production of chlorofluorocarbons for metered-dose inhalers

Acknowledging that chlorofluorocarbon consumption and production in Parties operating under paragraph 1 of Article 5 will cease from 1 January 2010, with possible essential-use exemptions,

Acknowledging also that many Parties operating under paragraph 1 of Article 5 import chlorofluorocarbon-free metered-dose inhalers from Parties not operating under paragraph 1 of Article 5,

Recognizing that campaign production offers potential advantages in lieu of annual essential‑use nominations under decision IV/25 to meet needs for pharmaceutical-grade chlorofluorocarbons,

Noting that decision XVIII/16, paragraph 12, requested the Technology and Economic Assessment Panel to assess “quantities for a limited campaign production of chlorofluorocarbons exclusively for metered-dose inhalers in Parties operating under paragraph 1 of Article 5 and Parties not operating under paragraph 1 of Article 5,”

Noting also that the Medical Technical Options Committee presented findings concerning the amounts of chlorofluorocarbons that may be needed for metered-dose inhalers only for Parties operating under paragraph 1 of Article 5 in 2008,

Acknowledging that the Medical Technical Options Committee has reported the need for additional information concerning the operations of a final campaign for Article 5 Parties except from one major manufacturing Party,

1. To request that the Technology and Economic Assessment Panel present a report to the Twenty-First Meeting of the Parties, preceded by a preliminary report to the Open-ended Working Group at its twenty-ninth meeting, concerning:
   1. The potential timing for final campaign production, taking into account, among other things, the information submitted in the nominations for 2010 and that some Parties operating under paragraph 1 of Article 5 may prepare essential use nominations for the first time for the Twenty-First Meeting of the Parties;
   2. Options for long-term storage, distribution, and management of produced quantities of pharmaceutical-grade chlorofluorocarbons before they are needed by Parties, including existing methods used by Parties not operating under paragraph 1 of Article 5;
   3. Options for minimizing the potential for too much or too little chlorofluorocarbons production as part of a final campaign;
   4. Contractual arrangements that may be necessary, considering the models currently used by Parties not operating under paragraph 1 of Article 5 that submit essential‑use nominations consistent with decision IV/25;
   5. Options for reducing production of non-pharmaceutical-grade chlorofluorocarbons, together with options for final disposal of such chlorofluorocarbons;
2. To request the Multilateral Fund Secretariat to report to the Open‑ended Working Group at its twenty-ninth meeting on the status of agreements to convert metered-dose inhaler manufacturing facilities located in Parties operating under paragraph 1 of Article 5 and the implementation of approved projects;